Table 1.
Clinicopathologic characteristics of plasma-based clinical pilot OC cases and healthy population-sampled control women.
| Characteristic | Ovarian cancer (n=91) | Healthy controls (n=91) |
|---|---|---|
| Age, years (median [IQR]) | 61 [57–68] | 61 [58–66] |
| BMI, kg/m2 (median [IQR]) | 27.25 [24.66–30.5] | 27.64 [22.95–31.45] |
| Pregnancies (median [IQR]) | 2 [1–3] | 2 [1–4] |
| Live births (median [IQR]) | 2 [1–3] | 2 [1–3] |
| Race | ||
| White | 75 (83%) | 89 (98%) |
| Non-White | 13 (14%) | 1 (1%) |
| Unknown | 3 (3%) | 1 (1%) |
| Tobacco Use | ||
| Current | 9 (10%) | 13 (14%) |
| Previous | 23 (25%) | 26 (29%) |
| Never | 59 (65%) | 52 (57%) |
| Menopausal Status | ||
| Premenopausal | 7 (8%) | 9 (10%) |
| Perimenopausal | 5 (5%) | 5 (5%) |
| Postmenopausal | 74 (81%) | 77 (85%) |
| Unknown | 5 (5%) | 0 (0%) |
| Histology | ||
| High grade serous | 73 (80%) | - |
| FIGO grade 1 or 2 endometrioid | 8 (9%) | - |
| Clear cell | 4 (4%) | - |
| Low grade serous | 4 (4%) | |
| Mucinous | 2 (2%) | - |
| Stage | ||
| I | 10 (11%) | - |
| II | 5 (5%) | - |
| III | 64 (70%) | - |
| IV | 12 (13%) | - |
| CA-125 U/mL (Median [IQR]) | 358.4 [119.2 – 1044.8] | 8.6 [5.8–12.5] |
BMI, body mass index; IQR, interquartile range